Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial Meeting Abstract
| Authors: | Kindler, H. L.; Campbell, N. P.; Wroblewski, K.; Maki, R. G.; D'Adamo, D. R.; Chow, W. A.; Gandara, D. R.; Antonescu, C.; Stadler, W. M.; Vokes, E. E. |
| Abstract Title: | Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial |
| Meeting Title: | 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 29 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2011 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2011-05-20 |
| Language: | English |
| ACCESSION: | WOS:000208880301026 |
| DOI: | 10.1200/jco.2011.29.15_suppl.10009 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 10009 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
